CompletedInterventionalPhase 1Phase 2Last updated Nov 19, 2024

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Overview

ClinicalTrials.gov ID: NCT03761914
Lead Sponsor: Sellas Life Sciences GroupINDUSTRY
Brief Summary: To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Sep 30, 2019Actual
Primary Completion Date: Jul 5, 2022Actual
Completion Date: Oct 27, 2022Actual

Study Record Dates

First Submitted: Nov 28, 2018
First Submitted that Met QC Criteria: Nov 30, 2018
First Posted: Dec 3, 2018Actual
Last Update Submitted that Met QC Criteria: Nov 12, 2024
Last Update Posted: Nov 19, 2024Actual
Last Verified: Nov 2024

NCT04040231Completed

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT01265433Completed

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

NCT01266083Completed

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

NCT02734160Completed

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

NCT03382600Completed

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

NCT02528357Completed

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)